Could intermittent L-arginine delivery , a strategy widely applied clinically to prevent nitrate tolerance to some degree, be considered and tested to reduce a potential arginine tolerance
The American Diabetes Association (ADA) guidelines recommend specific GLP-1 agonists with proven cardiovascular benefit (such as liraglutide, injectable semaglutide, and dulaglutide) for patients with type 2 diabetes and established atherosclerotic cardiovascular disease
While patients are showing some willingness to absorb cost hikes associated with reduced payer coverage for GLP-1 drugs, theyre far from the only stakeholders to be impacted by shifting policies: Biopharma Pharmaceutical developers could face slower market growth, particularly for newer indications like cardiovascular risk reduction and addiction treatment
The salt according to claim 1 or 2 wherein Xaa is Ala, bAla, Leu, Ile, Gly, Val, Nle or Nva, Yaa is Lys, Arg, Orn or His and Zaa is Glu, Asp, Aad or Apm
Many promising laboratory mechanisms fail to translate to meaningful human effects